X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Polivy® (polatuzumab vedotin-piiq) is a first-in-class anti-CD79b antibody-drug conjugate (ADC). It binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Polivy® intravenous infusion 30 mg and 140 mg [generic name: polatuzumab vedotin (genetical recombination)] for an additional indication of treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl), is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine-lpyl,Polatuzumab Vedotin
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Approval is based on pivotal data from the phase III POLARIX study, where Polivy (Polatuzumab Vedotin) plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOP.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 years.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
Polivy (polatuzumab vedotin) plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated diffuse large B-cell lymphoma in more than 20 years, potentially transforming treatment for people with this disease.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Polivy (polatuzumab vedotin) plus R-CHP significantly improved outcomes in previously untreated diffuse large B-cell lymphoma (DLBCL) compared to the standard of care for the first time in 20 year.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
Details:
First presentation of efficacy and safety data from the Phase III POLARIX study met its primary endpoint of improving progression-free survival, showing Polivy® (polatuzumab vedotin-piiq) plus Rituxan reduced disease worsening or death.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
Polivy is used as an off-the-shelf, fixed-duration treatment option in the relapsed or refractory DLBCL setting, and is approved in combination with bendamustine and MabThera/Rituxan for the treatment of R/R DLBCL in more than 60 countries worldwide.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2021
Details:
Longer-term data from the GO29365 study and results from 106 additional patients show continued survival benefit of this fixed-duration, off-the-shelf, Polivy combination.
Lead Product(s): Polatuzumab Vedotin,Bendamustine Hydrochloride,Rituximab
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Health Canada has granted market authorization to Polivy™(polatuzumab vedotin), in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL).
Lead Product(s): Polatuzumab Vedotin,Bendamustine Hydrochloride,Rituximab
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
This application is based on the results from a multicenter, single-arm Japanese phase II study that evaluated the efficacy and safety of the combination therapy of polatuzumab vedotin with bendamustine and rituximabin relapsed or refractory DLBCL.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
Polatuzumab vedotin in combination with bendamustine and rituximab achieved complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Polatuzumab Vedotin,Bendamustine Hydrochloride,Rituximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
Details:
Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology. It was developed and is commercialized by Roche/Genentech.
Lead Product(s): Polatuzumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
